Articles from Orvida Pharma Ltd

Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026

Findings support the Timed Up and Go (TUG) test combined with pain assessment as a promising functional endpoint for evaluating mobility impairment in palmoplantar epidermal differentiation disorders (pEDDs)

First Olmsted syndrome patient dosed in global Phase 1b study